Zobrazeno 11 - 20
of 55
pro vyhledávání: '"Dirk Huebner"'
Autor:
Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard Lutes, Andy Chi, Stefano Pileri
Publikováno v:
Critical Reviews in Oncology/Hematology. 99:228-240
Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory dise
Autor:
Andy Chi, Stefano Pileri, Richard Lutes, Pier Luigi Zinzani, Dirk Huebner, Vijayveer Bonthapally
Publikováno v:
Critical Reviews in Oncology/Hematology. 99:214-227
Peripheral T-cell lymphomas (PTCLs) tend to be aggressive and chemorefractory, with about 70% of patients developing relapsed/refractory disease. Prior to 2009, chemotherapies were the only options for relapsed/refractory PTCL, other than hematopoiet
Autor:
Susanna Varkey Ulahannan, Ursula A. Matulonis, Anthony W. Tolcher, Charles K. Anderson, Erika Hamilton, Kyriakos P. Papadopoulos, Joseph Buscema, Minal A. Barve, James Strauss, Donna Jarlenski, Debra L. Richardson, Melissa Lynne Johnson, Valerie M. Jansen, Rebecca Mosher, Timothy F. Burns, William Jeffery Edenfield, Corrine Zarwan, Dirk Huebner, Kathleen N. Moore, Deborah B. Doroshow
Publikováno v:
Journal of Clinical Oncology. 38:3549-3549
3549 Background: XMT-1536 is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, broadly expressed in NSCLC and ovarian cancer. XMT-1536 utilizes the Dolaflexin platform to deliver 10-12 DolaLock auristatin payload
Autor:
Bastian von Tresckow, Bingxia Wang, Jan Walewski, Noppadol Siritanaratkul, J. Koren, Wojciech Jurczak, Dirk Huebner, Suporn Chuncharunee, Ewa Paszkiewicz-Kozik, Andreas Engert, Muhit Ozcan, Andrzej Hellmann, Shalini Singh, Ai Sim Goh, Güner Hayri Özsan
Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1 center dot 8 mg/kg intravenously onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465d688536854e96a4e7359aa3cb1929
https://ruj.uj.edu.pl/xmlui/handle/item/99743
https://ruj.uj.edu.pl/xmlui/handle/item/99743
Autor:
Brittany Bahamon, Kimberly Perez, Jeffrey Ecsedy, Elizabeth Claire Dees, Robert L. Coleman, Angela DeMichele, Russell J. Schilder, Ursula A. Matulonis, Hadi Danaee, Dirk Huebner, Antoine Adenis, Kian Behbakht, Piotr Sawrycki, Bohuslav Melichar, Hyunjin Shin, Gerald Steven Falchook, Huifeng Niu, Jacob Zhang, Feng Gao
Publikováno v:
EBioMedicine
EBioMedicine, Elsevier, 2017, 25, pp.50-57. ⟨10.1016/j.ebiom.2017.10.015⟩
EBioMedicine, Vol 25, Iss C, Pp 50-57 (2017)
EBioMedicine, 2017, 25, pp.50-57. ⟨10.1016/j.ebiom.2017.10.015⟩
EBioMedicine, Elsevier, 2017, 25, pp.50-57. ⟨10.1016/j.ebiom.2017.10.015⟩
EBioMedicine, Vol 25, Iss C, Pp 50-57 (2017)
EBioMedicine, 2017, 25, pp.50-57. ⟨10.1016/j.ebiom.2017.10.015⟩
Background Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study in
Autor:
Andy I. Chen, Eric L. Sievers, Patrick J. Stiff, Tamas Masszi, Andy Chi, Dirk Huebner, Jerzy Holowiecki, Angelo Michele Carella, Craig H. Moskowitz, Emily K. Larsen, Dzhelil Osmanov, Edward Agura, Veronika Bachanova, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Alessandro M. Gianni, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
The Lancet. 385:1853-1862
High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, mo
Autor:
Eric Q. Wu, Oluwatoyin Shonukan, Andy Chi, Alexander R. Macalalad, Yi Liu, Vijayveer Bonthapally, Dirk Huebner, Hongbo Yang
Publikováno v:
Current Medical Research and Opinion. 31:993-1001
This meta-analysis evaluated the antitumor activity of brentuximab vedotin versus historical values in patients with relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplantation (ASCT).A systematic literature review identified studi
Autor:
Joseph D. Rosenblatt, Juan Pinelli, Pauline Brice, Keenan Fenton, Timothy M Illidge, Nancy L. Bartlett, Ranjana H. Advani, Joseph M. Connors, Jeffrey Matous, Barbara Pro, Michelle A. Fanale, Radhakrishnan Ramchandren, Andrei R. Shustov, Dana A. Kennedy, Dirk Huebner
Publikováno v:
Blood. 130(25)
This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first tr
Autor:
Madan Jagasia, Gary J. Schiller, David A. Rizzieri, Tibor Kovacsovics, Michael B. Maris, Christian Recher, Siddhartha Ganguly, Dirk Huebner, Stuart L. Goldberg, Robert K. Stuart, Karen Seiter, Hagop M. Kantarjian, David Avigan, Stefan Faderl, Farhad Ravandi, Parameswaran Hari, Meir Wetzler, Robert H. Collins, Jochen Greiner, Eunice S. Wang, Michael Craig, Norbert Vey, Michael J. Vasconcelles
Publikováno v:
Journal of Clinical Oncology. 30:2492-2499
Purpose To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). Patients and Methods Patients were randomly assigned
Autor:
Thomas Klingebiel, Keith J. August, Gregory Song, A. Llort, Lia Gore, Francesco Locatelli, Marta Pillon, S. Song, Nathalie Aladjidi, J. Kinley, C. Mauz-Koerholz, Stephen Daw, S. Zhang, Auke Beishuizen, Kathleen A. Neville, K. Hoffman, A. Medina-Sanson, Dirk Huebner, J. Sachs, Judith Landman-Parker
Publikováno v:
Hematological Oncology. 35:248-249